SOURCE: Washington G-2 Reports

MDx Conference Spring 2011

February 28, 2011 10:54 ET

Molecular Goes Mainstream! Washington G-2 Reports' Annual Molecular Diagnostics Conference to Focus on New Growth Opportunities for Labs

Faculty From Nation's Top Molecular Labs to Present Practical, Innovative Models and Strategies for Introducing -- and Optimizing -- MDx Operations

ARLINGTON, VA--(Marketwire - February 28, 2011) - Once an exclusive specialty of academic medical centers and reference laboratories, molecular diagnostic testing has officially reached the mainstream of laboratory medicine. With this in mind, Washington G-2 Reports' annual conference, which will take place April 13-15 in Boston at the Fairmont Copley Plaza, will bring clinical laboratory professionals and academic researchers face-to-face with other leading molecular labs, hospital programs, and pathology groups -- to discuss new opportunities, navigate regulatory changes, and share proven approaches for advancing the molecular testing business.

The three-day event aims to explore such practical considerations as the best ways for laboratories to build and optimize their molecular test menus; the latest testing opportunities and platform choices in an increasingly crowded market; how pharmacogenomics and personalized medicine are changing the interaction of clinical labs and physician practices; and the critical regulatory, legal, reimbursement, and coding changes that are on the horizon.

"Never before have there been so many powerful ways to seize upon scientific advances to expand clinical lab operations," according to Stephanie Murg, Managing Director of Washington G-2 Reports, "Therefore, we've assembled a world-class conference faculty from the rapidly growing field of molecular diagnostics to help labs of all types and sizes explore the possibilities."

The esteemed gathering includes keynote speakers Randy Scott, Ph.D., Executive Chairman of Genomic Health, and John Quackenbush, Ph.D., Professor of Computational Biology and Bioinformatics at the Harvard School of Public Health, plus a full roster of leaders in the areas of molecular business strategy, reimbursement, billing, legal, regulation, and results reporting:

  • Gyorgy Abel, M.D., Ph.D., Director, Clinical Immunology and Molecular Diagnostics/Clinical Chemistry, Department of Laboratory Medicine, Lahey Clinic
  • Andrea Ferreira-Gonzalez, Ph.D., Professor of Pathology and Director Molecular Diagnostics Laboratory, Virginia Commonwealth University Health System
  • Linh Hoang, M.D., Ph.D., Director of Genomic Medicine, Life Technologies
  • Jeffrey M. Jentzen, M.D., Professor and Director, Autopsy and Forensic Services, University of Michigan School of Medicine
  • Peter Kazon, Esq., Senior Counsel, Alston + Bird, LLP
  • Kevin Krenitsky, M.D., President, Enzo Clinical Labs
  • Bryan Moore, Ph.D., Group Marketing Manager, Roche Diagnostics
  • Stephanie Murg, Managing Director, Washington G-2 Reports
  • Bruce Quinn, M.D., Ph.D., Senior Health Policy Specialist, Foley Hoag LLP
  • Juan-Sebastian Saldivar, M.D., F.A.C.M.G., Director, Molecular Diagnostics, City of Hope
  • Patrick Terry, Partner and Principal, Pricing and Market Access Practice, Scientia Advisors, LLC
  • Gregory J. Tsongalis, Ph.D., Professor of Pathology and Director of Molecular Pathology, Dartmouth Hitchcock Medical Center
  • Diana Voorhees, Principal/CEO, DV & Associates, Inc.
  • Karen E. Weck, M.D., Professor and Director of the Molecular Genetics Laboratory, University of North Carolina School of Medicine
  • Dennis Weissman, Executive Editor and Founder, Washington G-2 Reports
  • Rina Wolf, Vice President of Commercialization Strategies, Consulting, and Industry Affairs, Xifin
  • Steven Wong, Ph.D., DABCC (TC), FACB, Professor of Pathology, Psychiatry, and Population-Health Epidemiology, Medical College of Wisconsin; Director, Toxicology, TDM, Pharmacogenomics and Proteomics, Medical College of Wisconsin; Scientific Director, Toxicology Department, Milwaukee County Medical Examiner's Office

To find out more, or to register for Washington G-2 Reports' Molecular Diagnostics Spring 2011 Conference in Boston, go to, email, or call 800.401.5937.

Special Early Bird Savings

Register before March 4, 2011, and save up to $300 on the conference and pre-conference workshops.

About Washington G-2 Reports

Washington G-2 Reports provides timely, accurate, and trusted analysis of industry and market trends, legal and regulatory developments, and technology and innovation that directly affect the operations, financial performance, and competitive position of diagnostic testing laboratories and related medical services providers.

Covering the diagnostic industry for over 30 years, Washington G-2 Reports delivers topical and analytical periodicals, proprietary research studies, and custom advisory services, and through live and virtual events, facilitates industry meetings and information exchanges.

Our mission is to deliver relevant, meaningful, and actionable findings on diagnostic industry markets, related regulatory changes, and lab operations. The organization strives to exceed client expectations and develop mutually beneficial relationships with industry leaders and influencers.

Washington G-2 Reports is a division of BNA Subsidiaries, LLC a leading provider of professional markets analysis.

Information on other Washington G-2 Reports products and services can be found at

Contact Information

  • Contact:

    Doug Anderson
    Vice President and Publisher
    Washington G-2 Reports
    Email Contact